Results 141 to 150 of about 665,294 (217)

Association Between BMI and the Efficacy and Safety of CDK4/6 Inhibitors in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Propensity Score Matched Cohort Study (CAMELIA)

MedComm – Oncology, Volume 5, Issue 4, December 2026.
This multicenter real‐world study showed that higher BMI (≥ 25 kg/m2) was independently associated with improved PFS in patients with HR+/HER2− advanced breast cancer receiving CDK4/6 inhibitors. Safety outcomes were comparable between BMI groups, and the findings were consistent across alternative BMI thresholds, suggesting the potential prognostic ...
Min Tian, Yijia Hua, Qian Liu, Nan Jin, Xinyu Wu, Kun Wang, Min Yan, Tao Sun, Chunfang Hao, Yanxia Zhao, Wei Li, Xiang Huang, Yongmei Yin   +12 more
wiley   +1 more source

Evaluating the Implementation Fidelity of the REJOIN (Using Exercise to Relieve Joint Pain and Improve Aromatase Inhibitor Adherence in Older Breast Cancer Survivors) Pilot Trial. [PDF]

J Appl Gerontol
Coffman EM, Zakrzewski SG, Leitzelar BN, Peters CH, Zimmer RP, Bluethmann SM.   +5 more
europepmc   +1 more source

Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis

Arthritis Care &Research, Volume 78, Issue 10, Page 1532-1543, October 2026.
Objective We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ‐R) and its risk factors among patients receiving long‐term HCQ with rheumatic diseases through a systematic review and meta‐analysis of observational studies that used spectral‐domain optical coherence tomography (SD‐OCT) for screening ...
Narsis Daftarian, Chloe Yue, Steve D. Levasseur, Hui Xie, J. Antonio Avina‐Zubieta   +4 more
wiley   +1 more source

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. [PDF]

Future Oncol
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source

Orchestrating the metastatic symphony: the role of extracellular vesicles in the epithelial–mesenchymal transition and pulmonary niche formation of breast cancer

Biological Reviews, Volume 101, Issue 5, Page 2103-2118, October 2026.
ABSTRACT The complexity of breast cancer (BC) lung metastasis lies in the capacity of tumour cells to interact efficiently with distant organs to promote colonisation, a process that involves the sophisticated coordination of inherent cellular plasticity and the remodelling of the distant microenvironment.
Jian Lu, Reza Shirazi Nia, Junjie Sun, Chrysa Filippopoulou, Daniel De Vega, Pengtao Hu, Heng Liang, Hang Yao, Chaoyue Pan, Xiaoyan Wu, Xidong Gu, Xiaohong Xie, Georgios Giamas   +12 more
wiley   +1 more source

Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary. [PDF]

Future Oncol
Rugo HS, Liu X, Li B, McRoy L, Chen C, Makari D, Layman RM, Brufsky A.   +7 more
europepmc   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to <i>ACAN</i> Mutation. [PDF]

AACE Endocrinol Diabetes
Ruiz DL, Delano A, Quintos JB.
europepmc   +1 more source

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla   +11 more
wiley   +1 more source

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer. [PDF]

Breast
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Cottu P, Curigliano G, Rugo HS.   +9 more
europepmc   +1 more source